Kotaro Miyao

634 total citations
34 papers, 377 citations indexed

About

Kotaro Miyao is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Kotaro Miyao has authored 34 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Hematology and 10 papers in Immunology. Recurrent topics in Kotaro Miyao's work include CAR-T cell therapy research (9 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Immune Cell Function and Interaction (6 papers). Kotaro Miyao is often cited by papers focused on CAR-T cell therapy research (9 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Immune Cell Function and Interaction (6 papers). Kotaro Miyao collaborates with scholars based in Japan, Thailand and United States. Kotaro Miyao's co-authors include Reona Sakemura, Seitaro Terakura, Makoto Murata, Tetsuya Nishida, Hitoshi Kiyoi, Jakrawadee Julamanee, Tatsunori Goto, Daisuke Koyama, Ryo Hanajiri and Keisuke Watanabe and has published in prestigious journals such as Blood, Applied Physics Letters and PLoS ONE.

In The Last Decade

Kotaro Miyao

31 papers receiving 374 citations

Peers

Countries citing papers authored by Kotaro Miyao

Since Specialization

Citations

This map shows the geographic impact of Kotaro Miyao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kotaro Miyao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kotaro Miyao more than expected).

Fields of papers citing papers by Kotaro Miyao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kotaro Miyao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kotaro Miyao. The network helps show where Kotaro Miyao may publish in the future.

Co-authorship network of co-authors of Kotaro Miyao

This figure shows the co-authorship network connecting the top 25 collaborators of Kotaro Miyao. A scholar is included among the top collaborators of Kotaro Miyao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kotaro Miyao. Kotaro Miyao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P99-3 The case report of NUT carcinoma administrated VDC-IE therapy 2024 ·Annals of Oncology ·Yuichiro Inagaki, (unknown), (unknown), Kotaro Miyao, (unknown), (unknown)	0
2	Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period 2024 ·Cytotherapy ·Takaaki Konuma, Kotaro Miyao, Hideki Nakasone, (unknown), Takahiro Fukuda, Masatsugu Tanaka, Yukiyasu Ozawa, Shuichi Ota, Toshiro Kawakita, Naoyuki Uchida, Masashi Sawa, Yuta Katayama, Nobuhiro Hiramoto, Tetsuya Eto, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda	2
3	Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma 2024 ·Frontiers in Pediatrics ·(unknown), (unknown), Elizabeth L. Siegler, Evandro D. Bezerra, Kotaro Miyao, Reona Sakemura	10
4	Efficacy and Safety of Reduced-Dose Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) in Patients over 80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) 2023 ·Blood ·Kotaro Miyao, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yuichiro Inagaki, Masashi Sawa	0
5	Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma? 2023 ·Frontiers in Oncology ·Kotaro Miyao, Hirofumi Yokota, Reona Sakemura	6
6	Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts 2023 ·International Journal of Hematology ·(unknown), Seitaro Terakura, Hidetsugu Fujigaki, Akinao Okamoto, Kotaro Miyao, Masashi Sawa, Takanobu Morishita, Tatsunori Goto, Yukiyasu Ozawa, Tetsuya Nishida, Nobuaki Fukushima, Kazutaka Ozeki, Ryo Hanajiri, Kuniaki Saito, Makoto Murata, Akihiro Tomita, Hitoshi Kiyoi	1
7	Clinical Benefit of Low-Dose Antithymocyte Globulin-Thymoglobulin as Graft-versus-Host Disease Prophylaxis in Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Identical Donors 2023 ·Transplantation and Cellular Therapy ·Yuki Takeuchi, Kotaro Miyao, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yuichiro Inagaki, Masashi Sawa	1
8	Feasibility of trimethoprim/sulfamethoxazole desensitization therapy in hematological diseases 2022 ·Clinical and Experimental Medicine ·(unknown), Kotaro Miyao, (unknown), (unknown), (unknown), (unknown), (unknown), Yuki Takeuchi, (unknown), Yuichiro Inagaki, Masashi Sawa	2
9	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence 2021 ·Bone Marrow Transplantation ·Makoto Murata, Seitaro Terakura, Atsushi Wake, Kotaro Miyao, Kazuhiro Ikegame, Naoyuki Uchida, Keisuke Kataoka, Toshihiro Miyamoto, Makoto Onizuka, Tetsuya Eto, Noriko Doki, Shuichi Ota, Maho Sato, Yoshiko Hashii, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Shinichiro Okamoto, Takanori Teshima	33
10	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival 2021 ·Molecular Therapy ·Jakrawadee Julamanee, Seitaro Terakura, (unknown), (unknown), Kotaro Miyao, Shingo Okuno, (unknown), (unknown), Daisuke Koyama, Tatsunori Goto, Ryo Hanajiri, Michael Hudecek, Peter Steinberger, Judith Leitner, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi	30
11	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia 2020 ·Biology of Blood and Marrow Transplantation ·Kotaro Miyao, Seitaro Terakura, Fumihiko Kimura, Takaaki Konuma, Koichi Miyamura, Masamitsu Yanada, Shinichi Kako, (unknown), Naoyuki Uchida, Takashi Toya, Yukiyasu Ozawa, Takahiro Fukuda, Masatsugu Tanaka, Masashi Sawa, Satoru Takada, Shuro Yoshida, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda	12
12	Donor single nucleotide polymorphism in ACAT1 affects the incidence of graft-versus-host disease after bone marrow transplantation 2019 ·International Journal of Hematology ·(unknown), Makoto Murata, Daisuke Koyama, Jakrawadee Julamanee, Shingo Okuno, (unknown), Kotaro Miyao, Tatsunori Goto, Yukiyasu Ozawa, Koichi Miyamura, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi	2
13	Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs 2018 ·Cancer Immunology Research ·Kotaro Miyao, Seitaro Terakura, Shingo Okuno, Jakrawadee Julamanee, Keisuke Watanabe, Hiroshi Hamana, Hiroyuki Kishi, Reona Sakemura, Daisuke Koyama, Tatsunori Goto, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi	16
14	Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease Tissues 2018 ·Biology of Blood and Marrow Transplantation ·Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Tomohiro Akashi, Shingo Okuno, (unknown), Jakrawadee Julamanee, (unknown), Kotaro Miyao, Reona Sakemura, Tatsunori Goto, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi	11
15	Quantitative Assessment of TCR Repertoire and Allo-Reactivity of Human Acute Gvhd Tissue-Infiltrating T Cells 2017 ·Blood ·Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Shingo Okuno, (unknown), (unknown), Jakrawadee Julamanee, Kotaro Miyao, Reona Sakemura, Tatsunori Goto, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi	2
16	High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype 2017 ·PLoS ONE ·Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Shingo Okuno, (unknown), Jakrawadee Julamanee, (unknown), Daiki Hirano, Kotaro Miyao, Reona Sakemura, Tatsunori Goto, Fumihiko Hayakawa, Aika Seto, Yukiyasu Ozawa, Koichi Miyamura, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi	3
17	A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration 2016 ·Cancer Immunology Research ·Reona Sakemura, Seitaro Terakura, Keisuke Watanabe, Jakrawadee Julamanee, (unknown), Kotaro Miyao, Daisuke Koyama, Tatsunori Goto, Ryo Hanajiri, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi	129
18	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy 2016 ·Journal of Immunotherapy ·Tatsunori Goto, Tetsuya Nishida, (unknown), Kotaro Miyao, Daisuke Koyama, Reona Sakemura, Ryo Hanajiri, Keisuke Watanabe, Nobuhiko Imahashi, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi	13
19	Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma 2014 ·International Journal of Hematology ·Kotaro Miyao, Reona Sakemura, (unknown), (unknown), (unknown), Tomonori Kato, Keiko Niimi, (unknown), Masashi Sawa	12
20	Verapamil Induces Protection of Alloxan but not Streptozotocin-Induced Diabetes in Rats 1988 ·Hormone and Metabolic Research ·Kenji Katsumata, Kotaro Miyao, Yoshinao Katsumata	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact